Navigation Links
Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection. The study was designed and conducted in collaboration with investigators at the University of Minnesota. Comparative analysis of the lead intranasal formulation, NRL-1, revealed promising pharmacokinetic results.  In its evaluation of a 10mg diazepam dose in the NRL-1 intranasal solution formulation, the study showed the following:

  • NRL-1 is well-tolerated, with only mild adverse events reported
  • Similar bioavailability to intravenous administration of diazepam (100% vs. 96%)
  • Tmax of 1.5 hours.
  • Cmax of approximately 272 ng/ml.
  • These values are comparable to those reported in the literature for Diastat® (rectal diazepam gel) at equivalent doses.  Diastat is the only approved therapy for the at home treatment of acute repetitive seizures.

  • "The results from this pilot study are very encouraging," commented Jim Cloyd, PharmD, University of Minnesota professor and principal investigator of the study, "The only approved drug to treat breakthrough seizures outside the hospital is diazepam rectal gel, a therapy that many older children and adults decline to use.  The ability to quickly and efficiently deliver, via intranasal administration, clinically relevant diazepam levels offers a more acceptable method of rescue therapy. The bioavailability and relatively low variability in exposure of the intranasal diazepam solution exceeded our expectations.  We look forward to further development of this important therapy."

    Dr. Wheless, Director of the LeBonheur Comprehensive Epilepsy Program at the University of Tennessee added, "Currently, the many patients with epilepsy do not have a viable option to help them deal with seizure emergencies at home, work or in social settings.  They end up with costly emergency room visits and hospital admissions.  The prospect of delivering diazepam intranasally to minimize seizure emergencies outside of the hospital setting is very attractive for physicians, patients and caregivers."

    "We are pleased to have reached this important milestone and excited about results previously unseen with intranasal delivery of benzodiazepines," stated David F. Hale, Chairman of Neurelis.   "Neurelis plans to continue to work with leading clinicians and researchers to advance this important therapy for patients who are living with the challenges of epilepsy."

    In the coming months, Neurelis plans to discuss the results of this study with the US Food and Drug Administration (FDA)to gain agreement on the next steps in the clinical progress of this product.  Data from the study is being submitted for review at the 2011 American Epilepsy Society Annual Meeting in December.

    About NRL-01

    NRL-01 (intranasal diazepam) is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer.  It is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity. There are over 2.7 million people with epilepsy in the United States with approximately 200,000 new patients diagnosed each year.  It is estimated that between 30% to 40% of these patients are uncontrolled on oral therapy and are at-risk for acute repetitive seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

    Presently, the only product approved for the treatment of acute repetitive seizures outside of the acute care setting, is a rectally administered formulation of diazepam called Diastat®.  Because of its rectal mode of administration, Diastat® is primarily used in younger pediatric patients.  The majority of patients with acute repetitive seizures, however, are seen in emergency rooms with many having an associated admission to the hospital, contributing to the estimated $15 billion annual economic burden.  Intranasal diazepam would provide a convenient alternative to either rectal administration of Diastat® or the need to visit the emergency room for intravenous administration of drugs.

    About Neurelis

    Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.Contact:

    David F. Hale858-756-2480Email:

    SOURCE Neurelis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
    2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    Post Your Comments:
    (Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
    (Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
    (Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
    Breaking Medicine Technology:
    (Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
    (Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo Inc , North ... , Sauna accessories help improve the bather experience in the sauna, and the ... for the purist looking for simplicity in design to accessories that encourage a ...
    (Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
    Breaking Medicine News(10 mins):